

PRECISION MEDICINE AND PHARMACEUTICAL INNOVATION ARE TRANSFORMING HEALTHCARE

Monawara Begum¹, Moidul Islam Judder², Rituraj bharadwaj³, Rajana James⁴, Gulbahar Begum⁵, Ms. Aditya Bora⁶, Abdul Kayum Al Aman⁷

¹Assistant Professor, Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Guwahati, Assam, India.

²Associate Professor, M.R. College of Pharmaceutical Sciences and Research, Bira, Balisha, North 24 pgs, West Bengal, India.

³Associate Professor and Head of Department, Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Guwahati, Assam, India.

⁴Assistant Professor, Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Guwahati, Assam, India.

⁵Lecturer, Department of Pharmaceutical Science, Girijananda Chowdhury University, Azara, Guwahati-17 Assam, India.

⁶Assistant professor, School of Pharmaceutical sciences, University of Science and Technology, Meghalaya

⁷Assistant professor, NEF college of pharmacy, Guwahati, Assam, India.

*Corresponding Author: Dr. Monawara Begum, Email: monawarabegum24@gmail.com

ABSTRACT

Precision medicine is transforming healthcare from a population-based approach to one that considers genetic, molecular, environmental, lifestyle, and clinical differences. It aims to develop preventive, diagnostic, and therapeutic treatments that are suitable for physiologically significant patient populations. Genomics, transcriptomics, proteomics, metabolomics, pharmacogenomics, AI, nanotechnology, biotechnology, and digital health are all accelerating this transition. Pharmaceutical sciences are vital because precision medicine requires targeted pharmaceuticals, biomarker-guided therapies, biologics, gene and cell therapies, RNA therapeutics, and personalized drug delivery systems. Pharmacogenomics can help predict variation in efficacy and toxicity, whilst companion diagnostics help select patients who are likely to benefit from specific medications.

Artificial intelligence and machine learning are increasingly being used in target selection, molecular design, virtual screening, pharmacokinetic/pharmacodynamic prediction, biomarker discovery, and clinical trial optimization. Nanomedicine could improve target selection, bioavailability, controlled release, and therapeutic index. The primary obstacles include data quality, privacy, algorithmic bias, regulatory science, cost, clinical validation, infrastructure, and equal access.

KEYWORDS: precision medicine, pharmaceutical innovation, artificial intelligence

INTRODUCTION

Modern medicine has made remarkable advances in the prevention, diagnosis, and treatment of numerous diseases; however, significant interindividual variability in disease susceptibility, clinical progression, therapeutic response, and adverse drug reactions remains a major challenge in clinical practice. Patients with the same clinical diagnosis and seemingly identical illness features may react differentially to the same treatment intervention. Differences in genetic background, epigenetic regulation, age, gender, environmental exposure, lifestyle, nutritional status, gut microbiota, concomitant medications, and comorbidities can all have an impact on disease biology and pharmacokinetic and pharmacodynamic responses. As a result, therapy options based on population averages may not yield optimal therapeutic outcomes for every patient.[1–4] The understanding of biological and clinical heterogeneity has aided the development of precision medicine, a strategy that seeks to enhance prevention, diagnosis, prognosis, and therapy by taking into account clinically meaningful biological and environmental differences among patient groups.

Precision medicine signifies a shift away from the traditional "one-size-fits-all" strategy and toward a more stratified, evidence-based approach to healthcare. Importantly, precision medicine does not require the development of a wholly unique drug or treatment for each individual patient. Rather, it seeks to identify biologically and clinically significant patient subgroups that differ in disease susceptibility, disease mechanisms, prognosis, or response to a specific intervention, allowing preventive or therapeutic strategies to be tailored to patients who are most likely to benefit.[1,5] This distinction is particularly relevant in complex disorders, including cancer, cardiovascular diseases, diabetes mellitus, neurological disorders, and autoimmune diseases, where disease phenotypes may result from numerous interacting genetic, molecular, environmental, and lifestyle variables.

Genomic diversity is a major factor influencing interindividual differences in illness risk and medication response. Advances in genome sequencing, genome-wide association studies, and molecular diagnostics have made it easier to identify genetic variants linked to disease susceptibility, therapeutic response, and adverse medication reactions. Pharmacogenomics, in particular, looks at how genetic variations affect drug pharmacokinetics, pharmacodynamics, efficacy, and toxicity. Variations in genes encoding drug-metabolizing enzymes, transporters, receptors, and other pharmacological targets might affect drug exposure or biological response, resulting in treatment failure or toxicity. [2,3,6]

In addition to inherited genetic variation, epigenetic mechanisms and environmental variables play a significant role in disease heterogeneity. DNA methylation, histone modifications, chromatin remodeling, and non-coding RNAs can all

influence gene expression without affecting the underlying DNA sequence. Diet, physical exercise, environmental contaminants, stress, drugs, and other exposures can all have an impact on these pathways, resulting in disparities in disease onset and response. Similarly, age, sex, nutritional status, organ function, and concomitant diseases can all influence medication absorption, distribution, metabolism, and excretion, as well as pharmacodynamic reactions. Such characteristics illustrate that precision medicine necessitates an integrated examination of numerous biological and clinical variables, rather than relying solely on genetic data.[1,4]

The human microbiome, particularly the gut bacteria, has also been identified as a key contributor to interindividual diversity in therapeutic outcomes. Microorganisms can directly metabolize medications or influence host metabolic, immunological, and inflammatory pathways, altering drug absorption, metabolism, efficacy, and toxicity. Variations in microbiome makeup between people may therefore contribute to disparities in treatment response that cannot be fully explained by host genetic variation.[7,8] The burgeoning area of pharmacomicrobiomics aims to define these interactions and identify microbiome-derived indicators that may potentially aid in patient classification and personalized therapy methods.

Rapid advances in omics technologies, such as genomes, transcriptomics, proteomics, metabolomics, and epigenomics, have also facilitated precision medicine. These methods yield multidimensional molecular data, which can be used to characterize disease-associated molecular signatures and uncover biomarkers for diagnosis, prognosis, patient stratification, and treatment selection. The combination of multi-omics data with clinical phenotypes has the potential to provide a more complete understanding of disease causes while also revealing molecularly defined subgroups that may respond differentially to certain therapies.[1,5] Such approaches are especially useful in cancer, where molecular profiling has permitted tumor classification based on genetic and molecular traits rather than only on anatomical site or histological markers.

The pharmaceutical sciences play a critical role in turning precision medicine concepts into clinically relevant medicines. Targeted drug delivery, biologics, gene therapy, cell therapy, RNA therapies, nanomedicine, and biomarker-guided drug development are all improving therapeutic specificity while reducing undesirable side effects. Precision drug delivery systems can be created to alter drug distribution, increase accumulation at pathological locations, control drug release, and improve the therapeutic index. Similarly, companion diagnostic techniques can identify patients with molecular traits that indicate a higher likelihood of responding to a specific therapeutic drug, allowing for better informed therapy selection.[3,9]

The increased availability of large-scale biomedical datasets has advanced the use of artificial intelligence (AI) and machine learning in precision medicine. Computational methods can combine genomic, molecular, imaging, clinical, and real-world data to uncover disease patterns, establish biomarkers, predict therapy response, and aid in drug discovery and development. Artificial intelligence-assisted techniques are rapidly being investigated for molecular target selection, virtual screening, drug design, pharmacokinetic/pharmacodynamic prediction, patient stratification, and clinical trial optimization. The integration of AI with multi-omics technologies and digital health is predicted to increase the potential to construct prediction models for personalized healthcare.

Despite its enormous potential, precision medicine's practical application continues to face numerous hurdles. These include biomedical data quality and interoperability, limited representation of diverse populations in genomic datasets, patient privacy protection, interpretation of complex molecular information, algorithmic bias, regulatory uncertainty, high costs of advanced diagnostics, insufficient infrastructure, and disparities in access to precision medicine. Furthermore, connections discovered in genomic or multi-omics investigations must be rigorously biologically and clinically validated before being used in normal clinical decision-making.[3,5,10] To ensure successful implementation, clinicians, pharmacologists, pharmacists, molecular biologists, bioinformaticians, data scientists, regulatory agencies, and pharmaceutical researchers must work together.

Overall, precision medicine is a developing framework for shifting healthcare away from broad treatment techniques and toward biologically informed, patient-centered, evidence-based therapies. Precision medicine offers the potential to improve therapeutic efficacy, minimize side effects, accelerate drug development, and maximize healthcare outcomes by combining genetic, genomic, environmental, lifestyle, microbiome, and clinical data with breakthroughs in pharmaceutical sciences. Continued developments in pharmacogenomics, multi-omics, AI, nanotechnology, and biomarker discovery, as well as robust clinical validation and equitable implementation, will be required to bring precision medicine's promise to routine clinical practice.

Evolution of Precision Medicine

Precision medicine has moved from the traditional "one-size-fits-all" treatment concept to a more personalized, molecularly guided approach. Conventional healthcare often entails disease diagnosis, routine therapy selection, clinical monitoring, and treatment change based on response or side effects. In contrast, precision medicine improves therapeutic results by including patient characterisation, molecular profiling, biomarker identification, patient stratification, focused therapy, continuous monitoring, and adaptive treatment.[11–12]

This transition was made possible by the advancements in molecular biology, recombinant DNA technologies, high-throughput screening, genomic sequencing, and bioinformatics. The Human Genome Project, finished in 2003, considerably increased our understanding of human genetic variation and its relevance to disease and therapeutic response.[13] Next-generation sequencing (NGS) then allowed for rapid and large-scale analysis of genomic and transcriptome data, facilitating illness classification, biomarker discovery, and therapeutic target selection.[14] Combining these technologies with pharmacogenomics and computational techniques has sped up the development of targeted and personalized treatments.[15] Overall, precision medicine reflects a shift away from population-based

treatment and toward biologically informed patient classification, allowing medicines to be selected based on genetic and clinical factors rather than diagnosis alone.

Precision Medicine versus Personalized Medicine

Precision medicine and customized medicine are frequently used interchangeably; however, precision medicine focuses on the discovery of clinically and physiologically significant patient subgroups based on genetic, molecular, environmental, and behavioral variables. Personalized medicine may suggest tailoring healthcare to an individual, but precision medicine typically focuses on stratifying patients into groups who are more likely to respond similarly to a specific intervention. As a result, precision medicine does not necessitate the creation of a novel drug or treatment for each individual patient.[16–17]

Major Components of Precision Medicine

Precision medicine integrates multiple biological and clinical information streams to develop a comprehensive multimodal patient profile. Major components and their pharmaceutical relevance are summarized below.

Pharmaceutical Innovation in Precision Medicine. Precision medicine drives innovation throughout the pharmaceutical development pipeline by allowing medicines to be tailored to particular molecular targets and physiologically defined patient populations. Advances in molecular biology, biomarker identification, pharmacogenomics, and drug delivery technologies have made it easier to create targeted small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), and other precision treatments.[21–24]

Targeted Small Molecule Therapies

Targeted small-molecule therapeutics aim to specifically modify disease-related enzymes, receptors, kinases, or intracellular signaling cascades. By interfering with specific molecular aberrations implicated in disease progression, these medicines can decrease pathological processes while potentially minimizing impacts on healthy tissues when compared to less selective therapies.[25] Targeted small compounds have proven particularly effective in oncology, where molecular characterisation of malignancies can reveal actionable genetic changes and guide treatment selection. Kinase inhibitors, enzyme inhibitors, receptor modulators, and pathway-specific inhibitors are some examples of drugs used to treat cancer and other inflammatory or metabolic illnesses. The clinical efficacy of these medicines is frequently dependent on identifying patients whose condition has the relevant molecular target or biomarker.[26]

Monoclonal Antibodies

Monoclonal antibodies (mAbs) are highly selective biological treatments that identify and bind to particular antigens, receptors, or signaling molecules implicated in disease progression. Their target specificity allows for selective control of pathogenic pathways, significantly improving the treatment of cancer, autoimmune illnesses, and chronic inflammatory disorders.[27] Trastuzumab, which targets HER2 in HER2-positive tumors; rituximab, which targets CD20 in B-cell malignancies; and the immune checkpoint inhibitors pembrolizumab and nivolumab, which target PD-1 to boost antitumor immunity. Adalimumab and infliximab, which target tumor necrosis factor- α (TNF- α), are commonly used for inflammatory and autoimmune illnesses.[28] These treatments show how molecular target identification and patient classification can enhance therapeutic precision.

Antibody Drug Conjugates

Antibody-drug conjugates (ADCs) are biopharmaceuticals that combine a monoclonal antibody with a strong cytotoxic or therapeutic payload via a specific chemical linker. The antibody component identifies a specific antigen that is preferentially expressed on target cells, allowing for selective delivery of the payload and subsequent cellular death. ADCs have emerged as a key type of precision medicines, particularly in oncology. Trastuzumab emtansine and trastuzumab deruxtecan are examples of HER2-targeted therapies, whereas brentuximab vedotin targets CD30, sacituzumab govitecan targets Trop-2, enfortumab vedotin targets Nectin-4, and gemtuzumab ozogamicin targets CD33 [29–31]. Their research illustrates the use of molecular diagnostics, antibody engineering, linker chemistry, and powerful drug payloads to promote selective therapeutic delivery.

Bispecific and multispecific therapeutics

Bispecific and multispecific medicines are biological substances developed to interact with two or more distinct molecular targets. Unlike traditional treatments, which target a single cell, these chemicals can connect many cells, disrupt several signaling pathways, and stimulate immunological responses. As a result, they increase the spectrum of molecularly targeted therapy and provide new opportunities for precision treatment. Multi-target therapies, such as blinatumomab (CD19 $\times$ CD3), teclistamab (BCMA $\times$ CD3), mosunetuzumab (CD20 $\times$ CD3), glofitamab (CD20 $\times$ CD3), and emicizumab (FIXa $\times$ FX), have shown promise in oncology and other complicated disorders[32]

Gene, RNA, and cell therapies

Gene, RNA, and cell treatments are cutting-edge precision medicine approaches that treat disease at the genetic, molecular, or cellular levels. These treatments can correct defective genes, modify gene expression, or use living cells as therapeutic agents. [33]

RNA Therapy

RNA-based treatments, such as mRNA, siRNA, antisense oligonucleotides, and microRNA, have an impact on protein production and gene expression. Patisiran is a siRNA therapy that targets transthyretin (TTR). Nusinersen is an antisense oligonucleotide used in spinal muscular atrophy.[34]

Nanotechnology and Precision Drug Delivery

Nanotechnology has become a critical component of precision medicine because it allows therapeutic substances to be designed, protected, delivered, and released at particular biological areas. Poor aqueous solubility, low bioavailability, fast disintegration, short circulation duration, and nonspecific tissue distribution are all potential limitations for conventional medicines. Nanocarriers can help to overcome these limitations by enhancing medication solubility, stability, pharmacokinetics, biodistribution, cellular absorption, and controlled release.[35–37] Their physicochemical features, such as particle size, surface charge, composition, and surface functionality, can be adjusted to meet therapeutic objectives.[38]

Major Nanocarrier Platforms

1. Liposomes and lipid nanoparticles Liposomes are made up of lipid bilayers that can encapsulate both hydrophilic and lipophilic medicines, whereas lipid nanoparticles are particularly useful for delivering nucleic acids such as mRNA and other RNA therapies. These devices can prevent sensitive payloads from degrading, improve intracellular delivery, and alter their pharmacokinetic behavior.[39] Their clinical success has proved the utility of lipid-based nanocarriers in precision medicine.

2. Polymeric nanoparticles

Polymeric nanoparticles provide for precise control of particle size, surface properties, drug loading, and release kinetics. Biodegradable polymers can be engineered to offer prolonged or regulated drug release, and surface modification with targeting ligands can aid in delivery to specific cells or tissues.[40]

4. Dendrimer with Nanogels

: Dendrimers have highly branching and structurally defined topologies, as well as numerous surface functional groups, which allow medicinal compounds and targeted ligands to be integrated. Nanogels are made up of nanoscale dimensions and a three-dimensional hydrophilic network that can hold medicines, proteins, or nucleic acids. Both platforms can be customized for regulated and stimuli-responsive administration.[41–42]

5. Metal Nanoparticles

: Metallic nanoparticles, notably gold-based systems, have sparked significant attention due to their unique optical, electrical, and surface properties. They can be used as platforms for drug delivery, molecular imaging, biosensing, photothermal therapy, and diagnostic-therapeutic combinations. However, their long-term biocompatibility, biodistribution, clearance, and safety must all be carefully assessed before they are used in clinical settings.[43]

6. Targeting Strategies

Passive targeting: Passive targeting takes advantage of variations in the vascular and physiological properties of sick tissues. Abnormal vascular permeability and decreased lymphatic outflow in tumors and some inflammatory tissues can encourage nanoparticle accumulation, a phenomenon known as the enhanced permeability and retention (EPR). However, the size of this effect varies greatly between tumors and people, limiting its prediction in clinical practice.[44]

Active targeting: Active targeting involves altering nanocarrier surfaces with antibodies, peptides, aptamers, carbohydrates, or other recognition ligands that bind to receptors or antigens expressed preferentially on target cells. Following systemic treatment, such interactions may increase cellular binding and uptake, resulting in better intracellular distribution of the therapeutic payload.[45]

Role of nanotechnology in precision medicine: The combination of nanotechnology, molecular targeting, and patient-specific biomarkers opens up possibilities for developing precision medication delivery systems. Nanocarriers can be tailored to match the biological characteristics of the disease and the physicochemical qualities of the therapeutic substance, and targeting ligands and stimuli-responsive mechanisms can further improve site-specific delivery. Thus, nanomedicine has the potential to improve therapeutic efficacy, reduce systemic toxicity, increase the therapeutic index, and facilitate the administration of new treatments such as RNA and gene-based medicines. Nonetheless, clinical translation remains difficult since nanomedicine effectiveness is dependent on biological barriers, protein corona formation, biodistribution, clearance, formulation repeatability, manufacturing scale-up, and patient-to-patient variability.[45–47] To achieve truly tailored and clinically predictable medication administration, future research must combine nanotechnology with biomarker-guided patient selection, pharmacokinetics, molecular profiling, and sophisticated imaging.

Application of Precision Medicine

Precision medicine is increasingly being used across numerous therapeutic domains to improve illness prevention, diagnosis, treatment selection, and monitoring by combining molecular, genetic, clinical, and lifestyle data.

1. Precision Oncology Cancer is a prominent application of precision medicine because cancers that arise from the same anatomical place can have distinct genetic and molecular causes. Genomic and molecular profiling can help uncover actionable mutations, biomarkers, and therapeutic targets, allowing for patient classification and focused therapy selection. Precision oncology can also help predict treatment outcomes and detect acquired resistance.[48]

2. Liquid biopsy Liquid biopsy is the extraction of circulating tumor-derived material from blood and other bodily fluids, namely circulating tumor DNA (ctDNA), RNA, or tumor cells. It provides a minimally invasive approach to

molecular characterisation, treatment response monitoring, resistance identification, and recurrence tracking, and may supplement traditional tissue biopsy.[50–51]

3. Precision medicine in cardiovascular disease. Cardiovascular disease is caused by intricate interplay between genetic, metabolic, environmental, and behavioral variables. Precision methods can help with cardiovascular risk prediction, the detection of inherited cardiovascular illnesses, pharmacogenomic therapy selection, tailored cholesterol and blood pressure control, and biomarker-based patient stratification.[52]

4. Precision medicine for diabetes and metabolic disorders: Diabetes is a complex condition with variations in insulin secretion, insulin sensitivity, hereditary risk, disease progression, and therapy response. Precision medicine may help with molecular classification, risk prediction, antidiabetic drug selection, personalized lifestyle and nutritional treatments, and continuous glucose monitoring. Integrating genetic, metabolomic, microbiome, lifestyle, and glucose-monitoring data has the potential to improve tailored metabolic treatment

5. Precision medicine in infectious diseases. Pathogen genomic sequencing can help discover genetic determinants of antibiotic resistance, aid in outbreak investigations, and improve pathogen characterization. Precision infectious disease techniques also include quick molecular diagnostics, resistance prediction, optimal antibiotic selection, host susceptibility variables, and host-directed therapy. These measures may improve treatment efficacy while also promoting antimicrobial stewardship.

CONCLUSION

Precision medicine marks a huge revolution in healthcare. Rather than assuming identical responses among patients with the same condition, it recognizes biological and environmental factors that influence disease and treatment outcomes. Pharmaceutical sciences are critical to this transformation: pharmacogenomics enables rational drug and dose selection; biomarkers identify responsive populations; targeted therapies address disease-associated pathways; biologics, gene, RNA, and cell therapies address increasingly specific mechanisms; and nanotechnology enhances delivery and targeting.

Ethics Statement

Not applicable; this is a review article and does not involve human participants or experimental animals.

Conflict of Interest

The author declares no conflict of interest.

Funding

No external funding was reported for this manuscript.

Author Contributions

The author contributed to the conception, literature review, analysis, interpretation, and preparation of the manuscript and approved the final version.

REFERENCES

1. Pirmohamed M. Pharmacogenomics: current status and future perspectives. *Nat Rev Genet.* 2023;24:350–362.
2. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature.* 2004;429:464–468.
3. Roden DM, George AL Jr. The genetic basis of variability in drug responses. *Nat Rev Drug Discov.* 2002;1:37–44.
4. National Institutes of Health. The Promise of Precision Medicine. NIH; reviewed January 21, 2025.
5. Scott SA. Personalizing medicine with clinical pharmacogenetics. *Genet Med.* 2011;13:987–995.
6. Peng C, et al. Targeting gut microbiota for precision medicine: focusing on the efficacy and toxicity of drugs. 2020.
7. Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. *Science.* 2017;356:eaag2770.
8. Weiss ST, McLeod HL, Flockhart DA, et al. Creating and evaluating genetic tests predictive of drug response. *Nat Rev Drug Discov.* 2008;7:568–574.
9. National Academies of Sciences, Engineering, and Medicine. Understanding Disparities in Access to Genomic Medicine. Washington, DC: National Academies Press; 2018
10. National Research Council. Toward Precision Medicine. Washington, DC: National Academies Press; 2011.
11. Hamburg MA, Collins FS. The path to personalized medicine. *N Engl J Med.* 2010;363:301–304.
12. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. *Nature.* 2004;431:931–945.
13. Metzker ML. Sequencing technologies—the next generation. *Nat Rev Genet.* 2010;11:31–46.
14. Ashley EA. Towards precision medicine. *Nat Rev Genet.* 2016;17:507–522
15. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
16. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med.* 2015;372:793–795.
17. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. *Genome Biol.* 2017;18:83.
18. Koppel N, Rekdal VM, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. *Science.* 2017;356:eaag2770.
19. Ashley EA. Towards precision medicine. *Nat Rev Genet.* 2016;17:507–522.
20. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med.* 2015;372:793–795.
21. Ashley EA. Towards precision medicine. *Nat Rev Genet.* 2016;17:507–522.

22. National Research Council. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington, DC: National Academies Press; 2011.
23. Takebe N, Majeed U, Lorusso PM. Targeted therapy for cancer: the next generation of therapeutics. *Nat Rev Clin Oncol*. 2015;12:625–639.
24. Sawyers C. Targeted cancer therapy. *Nature*. 2004;432:294–297.
25. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol*. 2010;10:317–327.
26. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. *Nat Rev Drug Discov*. 2010;9:767–774.
27. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. *Nat Rev Cancer*. 2012;12:278–287.
28. Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody–drug conjugates. *Nat Rev Drug Discov*. 2017;16:315–337.
29. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody–drug conjugates for cancer therapy. *Nat Rev Clin Oncol*. 2021;18:327–344.
30. Lambert JM, Morris CQ. Antibody–drug conjugates (ADCs) for personalized treatment of solid tumors: a review. *Adv Ther*. 2017;34:1015–1035.
31. National Institutes of Health. Appendix: Biomedical Definitions—Precision Medicine and Biomarkers. NIH; 2026.
32. Dagher J, Nassar M, Faour WH. Harnessing AI for precision medicine and its applications in genomics, systems pharmacology, and drug discovery. *European Journal of Pharmacology*. 2025;1006:178183. doi:10.1016/j.ejphar.2025.178183.
33. Saini JP, Thakur A, Yadav D. AI-driven innovations in pharmaceuticals: optimizing drug discovery and industry operations. *RSC Pharmaceuticals*. 2025;2:437–454. doi:10.1039/D4PM00323C.
34. Hajipour S, Ghiasvand A. Nanoparticle carriers for drug delivery: an updated review. *Pharm Nanotechnol*. 2024.
35. Dilliard SA, Siegwart DJ. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. *Nat Rev Mater*. 2023;8:282–300.
36. Cabral H, Li J, Miyata K, Kataoka K, et al. Controlling the biodistribution and clearance of nanomedicines. *Nat Rev Bioeng*. 2024;2:214–232.
37. Singh AP, Biswas A, Shukla A, Maiti P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. *Signal Transduct Target Ther*. 2019;4:33.
38. Xun Z, Li T, Xue X. The application strategy of liposomes in organ targeting therapy. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2024;16:e1955.
39. Beach MA, Nayanathara U, Gao Y, et al. Polymeric nanoparticles for drug delivery. *Chem Rev*. 2024;124:5505–5616.
40. Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. *Adv Pharm Bull*. 2015;5:305–313.
41. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nat Mater*. 2013;12:991–1003.
42. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. *Chem Soc Rev*. 2009;38:1759–1782.
43. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. *Nat Rev Cancer*. 2017;17:20–37.
44. Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. *Nat Rev Mater*. 2016;1:16014.
45. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. *Nat Mater*. 2013;12:991–1003..
46. Ashley EA. Towards precision medicine. *Nat Rev Genet*. 2016;17:507–522.
47. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. *Genome Med*. 2020;12:8.
48. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nat Rev Cancer*. 2017;17:223–238.
49. Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat Rev Genet*. 2019;20:71–88.
50. Ashley EA. The precision medicine initiative: a new national effort. *Nat Rev Drug Discov*. 2015;14:561–562.
51. Arnett DK, Claas SA. Pharmacogenetics and cardiovascular disease. *Clin Chem*. 2012;58:624–631.
52. Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: a consensus report from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2020;43:1617–1635.
- 53.